General
Preferred name
COBIMETINIB
Synonyms
RG-7420, GDC-0973, Cobimetinib Fumarate, XL-518, RG-7420, RG-7421, GDC-0973 ()
RG7420 ()
XL518 ()
GDC-0973 ()
Cobimetinib hemifumarate ()
CobimetinibGDC-0973GDC0973A-1180 ()
COTELLIC ()
GDC 0623 ()
GDC 0973 ()
GDC-0623 ()
RG 7420 ()
RG-7420 ()
RG-7421 ()
XL 518 ()
XL-518 ()
Cobimetinib (GDC-0973) ()
RG7420,XL518 ()
Gdc-0623 ()
XL-518 hemifumarate ()
GDC-0973 hemifumarate ()
COBIMETINIB FUMARATE ()
P&D ID
PD009336
CAS
934660-93-2
1369665-02-0
Tags
available
drug
Approved by
EMA
FDA
First approval
2015
Drug Status
approved
investigational
Max Phase
4.0
Drug indication
Metastatic melanoma
Neoplasm
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cobimetinib is an allosteric inhibitor of MEK serine/threonine protein kinases, with selectivity for MEK1 and MEK2 .
Note that cobimetinib has been erroneously referred to as cometinib and this has propagated in online resources- cometinib is not an official synonym. (GtoPdb)
DESCRIPTION Cobimetinib is an allosteric inhibitor of MEK serine/threonine protein kinases, with selectivity for MEK1 and MEK2 .
DESCRIPTION Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral MEK1 inhibitor with an IC50 of 4.2 nM for MEK1.
PRICE 100
DESCRIPTION For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor. (PKIDB)
DESCRIPTION Cobimetinib (GDC-0973) is a MEK1 inhibitor (IC50=4.2 nM) with selective and oral activity. Cobimetinib exhibits antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis. (TargetMol Bioactive Compound Library)
DESCRIPTION Cobimetinib, also known as GDC-0973 and XL-518, is a novel selective MEK inhibitor, and the IC50value against MEK1 is 4.2 nM, with potential antineoplastic activity. (BOC Sciences Bioactive Compounds)
Cell lines
2
Organisms
0
Compound Sets
27
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
EUbOPEN Chemogenomics Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
167
Properties
(calculated by RDKit )
Molecular Weight
531.06
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
2
cLogP
3.78
TPSA
64.6
Fraction CSP3
0.38
Chiral centers
1.0
Largest ring
6.0
QED
0.53
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Targets
MAP2K1
Target
Apoptosis
MEK
MEK1
Apoptosis related,MEK
Indication
melanoma
MOA
MEK inhibitor
Pathway
MAPK/ERK Pathway
MAPK
Solubility
DMSO
Recommended Cell Concentration
1 uM
Source data